1 active not recruiting, 1 recruiting, 1 unknown. 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow POLD1 Gene Mutation: new trials by email Literature Review of POLD1 Gene Mutation trials Research Report on POLD1 Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results Intervention Arm At-risk Relative/ARR Contacts, MyGene Portal, Standard of Care - BRCA1 Mutation, POLD1 Gene Mutation | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 1000 | 2022-12-01 | 2026-08-27 |
| Cohort of Tumors With POLE/D1 Mutation Tumors, POLE Exonuclease Domain Mutation | Unknown | Federation Francophone de Cancerologie Digestive | 100 | 2021-10-05 | 2024-07-08 | |
| Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability Laboratory Biomarker Analysis, Pembrolizumab - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Phase 2 | Active not recruiting | Rutgers, The State University of New Jersey | 21 | 2018-03-08 | 2026-04-03 |
Breast Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Adnexal Diseases (1) · Breast Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1) · Neoplasms (1) · Neoplasms by Site (1) · Neoplastic Processes (1) · Ovarian Diseases (1) · Pathologic Processes (1)
Standard of Care (1) · pembrolizumab (1)
Federation Francophone de Cancerologie Digestive (1) · Memorial Sloan Kettering Cancer Center (1) · Rutgers, The State University of New Jersey (1)
United States (2) · France (1)
Eugenia Girda, MD (1) · Kenneth Offit, MD, MPH (1)
P30CA072720 (1)